Embecta joins Tidepool to develop insulin pump

Embecta, the largest maker of disposable pen needles and insulin syringes for people withy diabetes, has announced plans to develop its own insulin pump, signaling a major shift in its business model.

Embecta (once known as BD) has advanced its pump project by partnering with Tidepool, a nonprofit organization that hosts software for people with diabetes and who received US clearance for a community-developed insulin dosing algorithm earlier this year, making it available for all interoperable hardware.

While Tidepool’s clearance covers the use of the algorithm in the management of Type 1 diabetes, Embecta is targeting the less-penetrated Type 2 insulin pump market and plans to work with Tidepool to develop open- and closed-loop systems.

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags